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ABSTRACT: Artemisinin-estrogen hybrids were for the first time both synthesized and investigated for their in vitro biological 
activity against malaria parasites (Plasmodium falciparum 3D7), human cytomegalovirus (HCMV) and a panel of human malignant 
cells of gynecological origin containing breast (MCF7, MDA-MB-231, MDA-MB-361, T47D) and cervical tumor cell lines (HeLa, 
SiHa, C33A). In terms of antimalarial efficacy hybrid 8 (EC50 = 3.8 nM) was about 2 times more active than its parent compound 
artesunic acid (7, EC50 = 8.9 nM) as well as the standard drug chloroquine (EC50 = 9.8 nM) and was, therefore, comparable to the 
clinically used dihydroartemisinin (6) (EC50 = 2.4 nM). Furthermore, hybrids 9–12 showed a strong antiviral effect with EC50 values 
in the submicromolar range (0.22-0.38 µM) and thus possess profoundly stronger anti-HCMV activity (approx. factor 25) than the 
parent compound artesunic acid (7, EC50 = 5.41 µM). These compounds also exerted a higher in vitro anti-HCMV efficacy than 
ganciclovir used as the standard of current antiviral treatment. In addition, hybrids 8–12 elicited substantially more pronounced 
growth inhibiting action on all cancer cell lines than their parent compounds and the reference drug cisplatin. The most potent agent, 
hybrid 12, exhibited submicromolar EC50 values (0.15–0.93 µM) against breast cancer and C33A cell lines.
Over the last three decades, steroids have become a prime 
focus of research in the field of medicinal chemistry due to their 
remarkable and diverse pharmacological properties, such as 
anticancer,1,2 anti-inflammatory,3,4 antiparasitic5 and antiviral 
activities.6,7 In particular, the two steroid hormones estrone (1) 
and 17-estradiol (2) (Figure 1) attracted a lot of attention, as 
these two estrogens are known to be involved in the 
development of various cancer types such as breast, colorectal, 
prostate and ovarian cancer.8 This led to the discovery of many 
different estradiol derivatives, which revealed to possess 
promising anticancer activity. In 2003, fulvestrant (3) an 
estrogen receptor antagonist was approved in the USA for the 
treatment of hormone-related breast cancer and since then it is 
used in clinics.9 2-Methoxyestradiol (4) an endogenous 
metabolite of 17-estradiol (2) turned out to effectively inhibit 
cancer cell proliferation both in vitro and in vivo and is currently 
investigated in advanced phases of clinical trials.10-15 One of the 
main advantages of 2-methoxyestradiol (4) over other 
biologically active estrogens is that it does not act as an estrogen 
receptor agonist and consequently is free of the typical 
hormone-related side effects.16,17 Furthermore, no serious 
toxicity was observed in clinical trials, when 
2-methoxyestradiol (4) was applied in pharmacological 
effective doses and therefore can be regarded as a promising 
anticancer agent.16,18
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Figure 1. Structures of estrone (1), 17-estradiol (2), 
fulvestrant (3), 2-methoxyestradiol (4), artemisinin (5), 
dihydroartemisinin (6) and artesunic acid (7).
As up to now no artemisinin-estrogen hybrids were reported 
in literature and our working group already could obtain 
remarkable results applying the hybridization concept,19-22 
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where two different biologically active substances are linked 
via a covalent bond,23,24 we planned to use estrogen derivatives 
as precursors for the synthesis of novel artemisinin hybrid 
molecules. Since its isolation in 1972 from the plant Artemisia 
annua L. by Youyou Tu, for which she received the Nobel Prize 
in 2015, artemisinin (5) was intensively investigated for its 
pharmacological activities.25,26 Artemisinin (5) exhibits not 
only antimalarial activity, for what it was mainly used in 
traditional Chinese medicine for several centuries,27-29 but it 
also revealed to possess antiviral30-33 and anticancer 
efficacy.34-38 These promising properties are also reflected in its 
semisynthetic derivatives dihydroartemisinin (6)39-41 and 
artesunic acid (7),42-45 bearing an alcohol or a carboxylic acid 
functionality and for that reason appear to be well-suited for 
hybridization purposes. Recently, it could be even 
demonstrated in a phase I clinical trial, which was performed in 
patients with metastatic breast cancer, that higher cumulative 
doses of artesunic acid are safe and well tolerated.46
Herein, we present the synthesis of five novel 
artemisinin-estrogen hybrids 8–12 (Figure 2) and the 
evaluation of their in vitro biological activity against malaria 
parasites (Plasmodium falciparum 3D7), human 
cytomegalovirus (HCMV) as well as a selection of human 
breast cancer cell lines (MCF7, MDA-MB-231, MDA-
MB-361, T47D) and cervical tumor cell lines (HeLa, SiHa, 
C33A).
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Figure 2. Novel hybrids 8–12 applied for biological tests against P. falciparum 3D7, HCMV as well as breast and cervical cancer.
Results and Discussion. Chemistry. Hybrids 8 and 9 
were prepared in moderate to good yields (81%/45%) by 
standard amide coupling between estradiol amine 13 and either 
artesunic acid (7) or artemisinin-derived carboxylic acid 15 
(Scheme 1). The reaction was conducted at room temperature 
overnight in a 1:1 mixture of CH3CN and CH2Cl2 as solvent and 
EDCI was solely used as coupling agent. Surprisingly, under 
these conditions no ester formation was observed as side 
reaction and the desired amides (8, 9) were the only products. 
The synthesis of the artemisinin-derived acid 15 was carried out 
in accordance to an already published protocol starting from 
dihydroartemisinin (6) (Scheme 2).47 The special feature of this 
artemisinin derivative is that it is free of the O-atom at C-10 and 
for that reason has been referred to a so-called C-10 non-acetal 
in the previous literature. This derivative has been considered 
to be more stable compared to the classical C-10-acetals such 
as artesunic acid (7).48 The other precursor, necessary for the 
synthesis of hybrids 8 and 9, 3-methoxy-estradiol-derived 
amine 13 (Scheme 2), was also prepared in analogy to 
procedures described in the literature.49-51 The stereoselectivity 
of the metal borohydride-mediated reduction of 16-azido 
estrone 3-methyl ether (17) towards 17- and 17-estradiol 
derivatives 18a/b can be achieved by selecting different alkali 
metals (Li, Na or K) as countercation. If bigger countercations 
like potassium are used, the 17-isomer is predominantly 
formed (57% yield), whereas smaller countercations such as 
lithium lead almost exclusively to the formation of the 
17-isomer (59% yield). 16-Azido 17-estradiol 3-methyl 
ether (18b) was then converted to the desired amine 13 by 
hydrazine monohydrate mediated reduction catalyzed by 
Raney-Ni (95% yield). The synthesis of hybrid 10 containing a 
1,2,3-triazole linkage was realized by a copper-catalyzed 
1,3-dipolar cycloaddition between 16-azido estrone 3-methyl 
ether (17) and artemisinin-derived alkyne 16, which afforded 
the desired product in 42% yield. Catalytic amounts of 
copper(II) sulfate and sodium ascorbate served as a source for 
copper(I), which was generated in situ. Alkyne 16 was prepared 
according to literature by etherification of 
dihydroartemisinin (6) with propargyl alcohol.52 As a final step, 
3-benzyloxy-17-hydroxy-16-hydroxymethyl-estrone 
derivative 14 was reacted with either artesunic acid (7) or 
artemisinin-derived acid 15 in a Steglich esterification in order 
to yield the desired hybrids 11 and 12 in 95/56%. DCC and 
DMAP were used as coupling agents and CH2Cl2 as solvent. 
The ester formation took place only at the primary alcohol 
group, which is probably attributed to its higher reactivity and 
less steric hindrance. The stability of target compounds 8–12 
was examined by heat exposure at 65 °C for 24 h or 40 °C for 
48 h, respectively. After applying these conditions, 1H NMR 
spectroscopy revealed that all synthesized hybrids remained 
sufficiently stable, i.e. less than 5% decomposition was detected 
in the recorded spectra. 
The hydroxy group at C-3 of all artemisinin-estrogen hybrids 
8-12 was protected via an ether group (benzyloxy or methoxy) 
to decrease the binding affinities of these novel compounds to 
the estrogen receptors and consequently reduce eventual 
hormone-related side effects.
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Scheme 1. Synthesis route for hybrids 8–12.
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Scheme 2. Synthesis of estrogen precursor 13 and artemisinin-derived acid 15.
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Biological Activity of the Hybrids. Antimalarial 
Activity. All synthesized hybrids 8–12 as well as their 
precursors, dihydroartemisinin (6), artesunic acid (7), estrone 
diol 14 and estrone azide 17 were investigated for their 
antimalarial activity against chloroquine-sensitive Plasmodium 
falciparum 3D7 parasites (Table 1). Hybrids 8–12 exhibited 
excellent to moderate antimalarial efficacy with EC50 values 
ranging from 3.8 to 128.8 nM, while its estrogen precursors 14 
and 17 showed no activity (EC50 > 16,000 nM). The best 
performing hybrid 8 was roughly 2 times more active than its 
parent compound artesunic acid (7) (EC50 = 8.9 nM) as well as 
the standard drug chloroquine (9.8 nM) and was therefore in 
terms of antimalarial efficacy comparable to the clinically used 
dihydroartemisinin (6) (EC50 = 2.4 nM). Hybrids 9 and 12 
containing a C-10 non-acetal artemisinin moiety were found to 
be 2 and 4 times, correspondingly, less active (EC50 values of 
7.7 and 128.8 nM) than their C-10 acetal counterparts 
(EC50(8) = 3.8 nM; EC50(11) = 34.2 nM). The same behavior 
was also observed in connection with artemisinin-quinazoline 
hybrids,53 which is in contrast to that of artemisinin-derived 
dimers.54 This indicates that different mechanisms might be 
involved for artemisinin-derived hybrids than for its dimeric 
structures. In addition, these EC50 values also demonstrate that 
a benzyloxy subunit at C-3 of the estrogen moiety (hybrids 11 
and 12) seems to be not beneficial for antimalarial activity of 
artemisinin-estrogen hybrids, as compounds 8 and 9 with a 
methoxy group were much more active. This result might be 
explained by the fact that hybrids 11 and 12 are more lipophilic 
than compounds 8 and 9 and as a result their cellular uptake into 
the malaria parasites is probably more limited.
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Table 1. EC50 values for hybrids 8-12 and selected reference compounds tested against P. falciparum 3D7 parasites, HCMV 
and various human breast cancer as well as cervical cancer cell lines
EC50 (µM)[e]
Compound MW (g/mol)
EC50 (nM) 
P.f. 3D7
EC50 (µM) 
HCMV MCF7 MDA-MB-231
MDA-
MB-361 T47D HeLa SiHa C33A
chloroquine 319.87 9.8 ± 2.8[a] - - - - - - - -
ganciclovir 579.98 - 2.60 ± 0.50[b] - - - - - - -
cisplatin 300.05 - - 5.78 19.13 3.76 9.78 12.43 7.87 3.69
artemisinin (5) 282.14 - > 10[c] - - - - - - -
DHA (6) 284.35 2.4 ± 0.4[a] > 10[c] 8.24 10.69 1.71 4.60 10.46 29.80 1.71
artesunic 
acid (7) 384.42 8.9 ± 1.9 5.41 ± 0.60
[d] 4.21 10.04 2.27 2.22 12.03 >30 1.83
estrone 
amine 13 301.43 - - 11.90 15.95 4.58 5.56 13.30 17.35 13.25
estrone diol 14 392.54 17,250 ± 586 - 12.89 12.75 2.77 8.32 12.80 7.75 12.20
estrone azide 17 325.41 >50,000 - >30 >30 >30 >30 >30 >30 >30
8 667.84 3.8 ± 0.8 2.44 ± 0.13 4.69 6.89 0.64 0.74 11.45 26.00 0.87
9 609.80 7.7 ± 2.4 0.23 ± 0.20 1.02 1.85 0.69 1.17 1.65 6.21 0.57
10 647.81 13.1 ± 1.8 0.24 ± 0.01 1.77 1.78 0.17 0.16 15.40 28.90 2.05
11 758.95 34.2 ± 3.2 0.38 ± 0.10 0.76 2.30 0.20 0.22 >30 28.43 1.73
12 700.91 128.8 ± 13.0 0.22 ± 0.00 0.45 0.86 0.18 0.93 14.22 16.12 0.15
[a] EC50 values have been previously reported.19 [b] EC50 value has been previously reported.43 [c] EC50 values have been previously 
reported.59 [d] EC50 value has been previously reported.58 [e] Mean values from two independent determinations with five parallel wells.
Anticytomegaloviral Activity. Furthermore, hybrids 8–12 
were analyzed for antiviral activity, focusing on human 
cytomegalovirus (recombinant HCMV AD169-GFP) used for 
the infection of cultured primary human foreskin fibroblasts 
(HFFs). Experimental determination of EC50 values was carried 
out in accordance to a previously established protocol55-58 and 
the results thereof are summarized in Table 1. Hybrids 9–12 
exerted a high antiviral efficacy with EC50 values in the 
submicromolar range (0.22–0.38 µM) and thus possessed a 
profoundly stronger anti-HCMV activity (approx. factor 25) 
than the parent compound artesunic acid (7). These compounds 
were also more effective than ganciclovir used as the gold 
standard of current antiviral treatment. In contrast to the 
determined antimalarial activities, C-10 non-acetal-linked 
artemisinin-derived hybrids 9 and 12 were more potent in anti-
HCMV activity than their C-10 acetal-linked counterparts 
(hybrids 8 and 11). This difference was most pronounced 
between compounds 8 and 9. In this case, hybrid 8 (EC50 = 
2.44 µM) was approximately. 10-times less active than hybrid 9 
(EC50 = 0.23 µM). Cell morphology, growth behavior and signs 
of cytotoxicity were routinely monitored by microscopic 
inspection under compound treatment along the period of 
infection (7 days, referring to a situation of multi-round viral 
replication) and no cytotoxicity was observed within the range 
of all concentrations tested.
Anticancer Activity. In a next step, hybrids 8–12 as well as 
their artemisinin and estrone precursors were investigated for 
their anticancer potential by means of MTT assay against a 
panel of human breast (MCF7, MDA-MB-231, MDA-MB-361, 
T47D) and cervical (HeLa, SiHa, C33A) cancer cell lines 
(Table 1). Estrone derivatives 13 and 14 exhibited 
antiproliferative action similar to that of reference agent 
cisplatin in terms of potency, while estrone azide 17 proved to 
be ineffective. Both artemisinin-derived compounds 6 and 7 
elicited growth inhibitory effects comparable to cisplatin with 
exception for SiHa cell line which was not sensitive towards 
them. All of the synthesized hybrids 8–12 exhibited 
substantially pronounced antiproliferative action on breast 
cancer cells. The most potent hybrid 12 displayed 
submicromolar EC50 values (0.18-0.93 µM) indicating an 
outstanding increase in the efficacy when compared with the 
actions of the building elements of the molecule. In the case of 
cervical cell lines, the actions of the precursors were modest and 
the increase in the anticancer potency were less dynamic though 
compound 9 was remarkable on all utilized cells and hybrid 12 
exhibited promising action on C33A cell line.
Conclusion. In conclusion, several estradiol/estrone 
derivatives could be coupled to artemisinin for the first time, 
thereby forming five novel artemisinin-estrogen hybrids 8–12. 
These were investigated for their in vitro biological activity 
against malaria parasites (Plasmodium falciparum 3D7), 
human cytomegalovirus (HCMV) and a selection of human 
breast cancer as well as cervical cancer cell lines. All 
synthesized hybrids exhibited a strong antimalarial effect with 
EC50 values in the nanomolar range (3.8-128.8 nM). The most 
active hybrid in terms of antimalarial efficacy, compound 8, 
was about 2 times more active than its parent compound 
artesunic acid (7) (EC50 = 8.9 nM) as well as the standard drug 
chloroquine (9.8 nM) and was therefore comparable to the 
clinically used dihydroartemisinin (6) (EC50 = 2.4 nM). 
Furthermore, hybrids 9–12 exhibited high antiviral activity 
(EC50 = 0.22-0.38 µM) and thus represent a group of very 
attractive, novel chemical structures exerting a pronounced 
anti-HCMV activity mostly in the submicromolar range, which 
appears even superior to the in vitro efficacy of reference drug 
ganciclovir. Besides the antimicrobial properties of the 
prepared agents they exhibited a pronounced growth inhibitory 
action against a panel of human cancer cells. EC50 values of the 
hybrids were lower by orders of magnitude when compared 
with those of the building blocks. Based on the results of the 
presented antiproliferative assays, hybrid molecules designed 
and synthesized from artemisinin and estrone elements can be 
regarded as potential lead molecules for development of 
innovative anticancer agents. All in all, a relatively low level of 
efforts in chemical synthesis was sufficient to generate very 
promising pharmacological candidate compounds, which once 
Page 4 of 7
ACS Paragon Plus Environment
ACS Medicinal Chemistry Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
again highlights the attractiveness of the hybridization concept. 
We like to stress that this concept possesses a broad 
translational potential and might be useful for a number of 
future drug and biomedical developments.
ASSOCIATED CONTENT 
Supporting Information
The Supporting Information is available free of charge on the ACS 
Publications website. Experimental conditions and procedures as 
well as spectral data for precursors 13, 15, 16, 18a/b, 19 and 20 and 
target compounds 8-12; recorded spectra of target compounds; 
details of cell lines and reagents as well as cell viability assay for 
biological evaluation. (PDF)
AUTHOR INFORMATION
Corresponding Author
* S.B. Tsogoeva, Fax: (+) 49 9131 85 22865; 
E-mail: svetlana.tsogoeva@fau.de 
ACKNOWLEDGMENT 
S.B.T. is grateful to the Deutsche Forschungsgemeinschaft (DFG) 
for generous funding by grant TS 87/16-3 and to the 
Interdisciplinary Center for Molecular Materials (ICMM), the 
Graduate School Molecular Science (GSMS), as well as Emerging 
Fields Initiative (EFI) “Chemistry in Live Cells” supported by 
Friedrich-Alexander-Universität Erlangen-Nürnberg for research 
funding. Financial support by the National Research, Development 
and Innovation Office-NKFIH through project GINOP-2.3.2.-15-
2016-00038 (Hungary) is gratefully acknowledged. Furthermore, 
the authors are grateful for financial support from OTKA K113150 
and K109293. The work of Anita Kiss was supported by a PhD 
Fellowship of the Talentum Fund of Richter Gedeon Plc. Renáta 
Minorics was supported by a János Bolyai Research Scholarship of 
the Hungarian Academy of Sciences.
DEDICATION 
This paper is dedicated to Professor Youyou Tu.
ABBREVIATIONS
DCC, N,N’-dicyclo-hexylcarbodiimide; DCE, 1,2-dichloroethane; 
DHA, dihydroartemisinin; DMAP, 4-(dimethylamino)pyridine; 
EDCI, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide; EtOAc, 
ethyl acetate; eq, equivalent; GFP, green fluorescent protein; 
HCMV, human cytomegalovirus; HFFs, human foreskin 
fibroblasts.
REFERENCES
1. Arenas-González, A.; Mendez-Delgado, L. A.; Merino-Montiel, 
P.; Padrón, J. M.; Montiel-Smith, S.; Vega-Báez, J. L.; Meza- Reyes, 
S. Synthesis of monomeric and dimeric steroids containing 
[1,2,4]triazolo[1,5-a]pyrimidines. Steroids 2016, 116, 13-19.
2. Alsayari, A.; Kopel, L.; Ahmed, M. S.; Pay, A.; Carlson, T.; 
Halaweish, F. T. Design, synthesis, and biological evaluation of 
steroidal analogs as estrogenic/anti-estrogenic agents. Steroids 2017, 
118, 32-40.
3. Khan, M. O. F.; Lee, H. J. Synthesis and Pharmacology of Anti-
inflammatory Steroidal Antedrugs. Chem. Rev. 2008, 108, 5131-5145.
4. Biju, P.; Bitar, R.; Lim, Y.-H.; Wang, Y.; Berlin, M.; Aslanian, 
R.; McCormick, K. Synthesis of novel anti-inflammatory steroidal 
macrocycles using ring closing metathesis reaction. Tetrahedron Lett. 
2015, 56, 636-638.
5. Krieg, R.; Jortzik, E.; Goetz, A. A.; Blandin, S.; Wittlin, S.; 
Elhabiri, M.; Rahbari, M.; Nuryyeva, S.; Voigt, K.; Dahse, H. M.; 
Brakhage, A.; Beckmann, S.; Quack, T.; Grevelding, C. G.; Pinkerton, 
A. B.; Schonecker, B.; Burrows, J.; Davioud-Charvet, E.; Rahlfs, S.; 
Becker, K. Arylmethylamino steroids as antiparasitic agents. Nat. 
Commun. 2017, 8, 14478.
6. Nadaraia, N. S.; Onashvili, E. O.; Kakhabrishvili, M. L.; 
Barbakadze, N. N.; Sylla, B.; Pichette, A. Synthesis and Antiviral 
Activity of Several N-Containing 5α-STEROIDS. Chem. Nat. Compd. 
2016, 52, 853-855.
7. Zhao, J. L.; Zhang, M.; Liu, J. M.; Tan, Z.; Chen, R. D.; Xie, K. 
B.; Dai, J. G. Bioactive steroids and sorbicillinoids isolated from the 
endophytic fungus Trichoderma sp. Xy24. J. Asian Nat. Prod. Res. 
2017, 1-8.
8. Deroo, B. J.; Korach, K. S. Estrogen receptors and human 
disease. J. Clin. Invest. 2006, 116, 561-570.
9. Jones, S. E. Fulvestrant: an estrogen receptor antagonist that 
downregulates the estrogen receptor. Semin. Oncol. 2003, 30, 14-20.
10. Fotsis, T.; Zhang, Y.; Pepper, M. S.; Adlercreutz, H.; Montesano, 
R.; Nawroth, P. P.; Schweigerer, L. The endogenous oestrogen 
metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses 
tumour growth. Nature 1994, 368, 237-239.
11. Tevaarwerk, A. J.; Holen, K. D.; Alberti, D. B.; Sidor, C.; Arnott, 
J.; Quon, C.; Wilding, G.; Liu, G. Phase I Trial of 2-Methoxyestradiol 
(2ME2, Panzem®) NanoCrystal® Dispersion (NCD®) in Advanced 
Solid Malignancies. Clin. Cancer Res. 2009, 15, 1460-1465.
12. Fukui, M.; Zhu, B. T. Mechanism of 2-methoxyestradiol-
induced apoptosis and growth arrest in human breast cancer cells. Mol. 
Carcinog. 2009, 48, 66-78.
13. Kulke, M. H.; Chan, J. A.; Meyerhardt, J. A.; Zhu, A. X.; 
Abrams, T. A.; Blaszkowsky, L. S.; Regan, E.; Sidor, C.; Fuchs, C. S. 
A prospective phase II study of 2-methoxyestradiol administered in 
combination with bevacizumab in patients with metastatic carcinoid 
tumors. Cancer Chemother. Pharmacol. 2011, 68, 293-300.
14. Bruce, J. Y.; Eickhoff, J.; Pili, R.; Logan, T.; Carducci, M.; 
Arnott, J.; Treston, A.; Wilding, G.; Liu, G. A phase II study of 2-
methoxyestradiol nanocrystal colloidal dispersion alone and in 
combination with sunitinib malate in patients with metastatic renal cell 
carcinoma progressing on sunitinib malate. Invest. New Drugs 2012, 
30, 794-802.
15. Gorska, M.; Kuban-Jankowska, A.; Slawek, J.; Wozniak, M. 
New Insight into 2-Methoxyestradiol- a Possible Physiological Link 
between Neurodegeneration and Cancer Cell Death. Curr. Med. Chem. 
2016, 23, 1513-1527.
16. Lakhani, N. J.; Sarkar, M. A.; Venitz, J.; Figg, W. D. 2-
Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 
2003, 23, 165-72.
17. Luc, J. G. Y.; Paulin, R.; Zhao, J. Y.; Freed, D. H.; Michelakis, 
E. D.; Nagendran, J. 2-Methoxyestradiol: A Hormonal Metabolite 
Modulates Stimulated T-Cells Function and proliferation. Transplant. 
Proc. 2015, 47, 2057-2066.
18. Perez-Sepulveda, A.; España-Perrot, P. P.; Norwitz, E. R.; 
Illanes, S. E. Metabolic Pathways Involved in 2-Methoxyestradiol 
Synthesis and Their Role in Preeclampsia. Reprod. Sci. 2013, 20, 1020-
1029.
19. Reiter, C.; Fröhlich, T.; Zeino, M.; Marschall, M.; Bahsi, H.; 
Leidenberger, M.; Friedrich, O.; Kappes, B.; Hampel, F.; Efferth, T.; 
Tsogoeva, S. B. New efficient artemisinin derived agents against 
human leukemia cells, human cytomegalovirus and Plasmodium 
falciparum: 2nd generation 1,2,4-trioxane-ferrocene hybrids. Eur. J. 
Med. Chem. 2015, 97, 164-172.
20. Fröhlich, T.; Ndreshkjana, B.; Muenzner, J. K.; Reiter, C.; 
Hofmeister, E.; Mederer, S.; Fatfat, M.; El-Baba, C.; Gali-Muhtasib, 
H.; Schneider-Stock, R.; Tsogoeva, S. B. Synthesis of Novel Hybrids 
of Thymoquinone and Artemisinin with High Activity and Selectivity 
Against Colon Cancer. Chem. Med. Chem. 2017, 12, 226-234.
21. Held, F. E.; Guryev, A. A.; Fröhlich, T.; Hampel, F.; Kahnt, A.; 
Hutterer, C.; Steingruber, M.; Bahsi, H.; von Bojnič ić -Kninski, C.; 
Mattes, D. S.; Foertsch, T. C.; Nesterov-Mueller, A.; Marschall, M.; 
Tsogoeva, S. B. Facile access to potent antiviral quinazoline 
heterocycles with fluorescence properties via merging metal-free 
domino reactions. Nature communications 2017, 8, 15071.
Page 5 of 7
ACS Paragon Plus Environment
ACS Medicinal Chemistry Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. Fröhlich, T.; Reiter, C.; Saeed, M. E. M.; Hutterer, C.; Hahn, F.; 
Leidenberger, M.; Friedrich, O.; Kappes, B.; Marschall, M.; Efferth, 
T.; Tsogoeva, S. B. Synthesis of Thymoquinone-Artemisinin Hybrids: 
New Potent Antileukemia, Antiviral and Antimalarial Agents. ACS 
Med. Chem. Lett. 2017, 9, 534-539.
23. Mehta, G.; Singh, V. Hybrid systems through natural product 
leads: An approach towards new molecular entities. Chem. Soc. Rev. 
2002, 31, 324-334.
24. Tietze, L. F.; Bell, H. P.; Chandrasekhar, S. Natural Product 
Hybrids as New Leads for Drug Discovery. Angew. Chem. Int. Ed. 
2003, 42, 3996-4028.
25. Tu, Y. The discovery of artemisinin (qinghaosu) and gifts from 
Chinese medicine. Nat. Med. 2011, 17, 1217-1220.
26. Su, X.-z.; Miller, L. H. The discovery of artemisinin and Nobel 
Prize in Physiology or Medicine. Sci. China: Life Sci. 2015, 58, 1175-
1179.
27. Qinghaosu Antimalarial Coordinating Research Group. 
Antimalaria studies on Qinghaosu. Chin. Med. J. (Engl. Ed.) 1979, 12, 
811-816.
28. Klayman, D. Qinghaosu (artemisinin): an antimalarial drug from 
China. Science 1985, 228, 1049-1055.
29. Miller, L. H.; Su, X. Artemisinin: Discovery from the Chinese 
Herbal Garden. Cell 2011, 146, 855-858.
30. Romero, M. R.; Serrano, M. A.; Vallejo, M.; Efferth, T.; Alvarez, 
M.; Marin, J. J. Antiviral effect of artemisinin from Artemisia annua 
against a model member of the Flaviviridae family, the bovine viral 
diarrhoea virus (BVDV). Planta Med. 2006, 72, 1169-1174.
31. Paeshuyse, J.; Coelmont, L.; Vliegen, I.; Van hemel, J.; 
Vandenkerckhove, J.; Peys, E.; Sas, B.; De Clercq, E.; Neyts, J. Hemin 
potentiates the anti-hepatitis C virus activity of the antimalarial drug 
artemisinin. Biochem. Biophys. Res. Commun. 2006, 348, 139-144.
32. Efferth, T.; Romero, M. R.; Wolf, D. G.; Stamminger, T.; Marin, 
J. J.; Marschall, M. The antiviral activities of artemisinin and 
artesunate. Clin. Infect. Dis. 2008, 47, 804-811.
33. Parvez, M. K.; Arbab, A. H.; Al-Dosari, M. S.; Al-Rehaily, A. J. 
Antiviral Natural Products Against Chronic Hepatitis B: Recent 
Developments. Curr. Pharm. Des. 2016, 22, 286-293.
34. Woerdenbag, H. J.; Moskal, T. A.; Pras, N.; Malingre, T. M.; el-
Feraly, F. S.; Kampinga, H. H.; Konings, A. W. Cytotoxicity of 
artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J. Nat. 
Prod. 1993, 56, 849-56.
35. Singh, N. P.; Lai, H. C. Artemisinin induces apoptosis in human 
cancer cells. Anticancer Res. 2004, 24, 2277-2280.
36. Efferth, T. Molecular pharmacology and pharmacogenomics of 
artemisinin and its derivatives in cancer cells. Curr. Drug Targets 
2006, 7, 407-421.
37. Lai, H. C.; Singh, N. P.; Sasaki, T. Development of artemisinin 
compounds for cancer treatment. Invest. New Drugs 2013, 31, 230-246.
38. Li, Z.; Li, Q.; Wu, J.; Wang, M.; Yu, J. Artemisinin and Its 
Derivatives as a Repurposing Anticancer Agent: What Else Do We 
Need to Do? Molecules 2016, 21.
39. Crespo-Ortiz, M. P.; Wei, M. Q. Antitumor Activity of 
Artemisinin and Its Derivatives: From a Well-Known Antimalarial 
Agent to a Potential Anticancer Drug. J. Biomed. Biotechnol. 2012, doi: 
10.1155/2012/247597.
40. Sun, H.; Meng, X.; Han, J.; Zhang, Z.; Wang, B.; Bai, X.; Zhang, 
X. Anti-cancer activity of DHA on gastric cancer - An in vitro and in 
vivo study. Tumour Biol. 2013, 34, 3791-3800.
41. Xu, G.; Zou, W.-Q.; Du, S.-J.; Wu, M.-J.; Xiang, T.-X.; Luo, Z.-
G. Mechanism of dihydroartemisinin-induced apoptosis in prostate 
cancer PC3 cells: An iTRAQ-based proteomic analysis. Life Sci. 2016, 
157, 1-11.
42. Looareesuwan, S.; Wilairatana, P.; Vanijanonta, S.; 
Pitisuttithum, P.; Ratanapong, Y.; Andrial, M. Monotherapy with 
sodium artesunate for uncomplicated falciparum malaria in Thailand: a 
comparison of 5- and 7-day regimens. Acta Trop. 1997, 67, 197-205.
43. Kaptein, S. J. F.; Efferth, T.; Leis, M.; Rechter, S.; Auerochs, S.; 
Kalmer, M.; Bruggeman, C. A.; Vink, C.; Stamminger, T.; Marschall, 
M. The anti-malaria drug artesunate inhibits replication of 
cytomegalovirus in vitro and in vivo. Antiviral Res. 2006, 69, 60-69.
44. Michaelis, M.; Kleinschmidt, M. C.; Barth, S.; Rothweiler, F.; 
Geiler, J.; Breitling, R.; Mayer, B.; Deubzer, H.; Witt, O.; Kreuter, J.; 
Doerr, H. W.; Cinatl, J.; Cinatl, J., Jr. Anti-cancer effects of artesunate 
in a panel of chemoresistant neuroblastoma cell lines. Biochem. 
Pharmacol. 2010, 79, 130-136.
45. Zhou, X.; Sun, W. J.; Wang, W. M.; Chen, K.; Zheng, J. H.; Lu, 
M. D.; Li, P. H.; Zheng, Z. Q. Artesunate inhibits the growth of gastric 
cancer cells through the mechanism of promoting oncosis both in vitro 
and in vivo. Anti-cancer drugs 2013, 24, 920-927.
46. von Hagens, C.; Walter-Sack, I.; Goeckenjan, M.; Osburg, J.; 
Storch-Hagenlocher, B.; Sertel, S.; Elsässer, M.; Remppis, B. A.; Edler, 
L.; Munzinger, J.; Efferth, T.; Schneeweiss, A.; Strowitzki, T. 
Prospective open uncontrolled phase I study to define a well-tolerated 
dose of oral artesunate as add-on therapy in patients with metastatic 
breast cancer (ARTIC M33/2). Breast Cancer Res. Treat. 2017, 1-11.
47. Stocks, P. A.; Bray, P. G.; Barton, V. E.; Al-Helal, M.; Jones, 
M.; Araujo, N. C.; Gibbons, P.; Ward, S. A.; Hughes, R. H.; Biagini, 
G. A.; Davies, J.; Amewu, R.; Mercer, A. E.; Ellis, G.; O'Neill, P. M. 
Evidence for a Common Non-Heme Chelatable-Iron-Dependent 
Activation Mechanism for Semisynthetic and Synthetic Endoperoxide 
Antimalarial Drugs. Angew. Chem. Int. Ed. 2007, 46, 6278-6283.
48. Posner, G. H.; Ploypradith, P.; Parker, M. H.; O’Dowd, H.; Wou, 
S.-H.; Northrop, J.; Krasavin, M.; Dolan, P.; Kensler, T. W.; Xie, S.; 
Shapiro, T. A. Antimalarial, antiproliferative, and antitumor activities 
of artemisinin-derived, chemically robust, trioxane dimers. J. Med. 
Chem. 1999, 42, 4275-4280.
49. Schönecker, B.; Ponsold, K. Steroide. XXX. Synthesen vicinaler 
Steroid-Azidoketone. J. prakt. Chem. 1971, 313, 817-824.
50. Schönecker, B.; Ponsold, K. Steroide—XL. Tetrahedron 1975, 
31, 1113-1118.
51. Becker, K.; Krieg, R.; Schönecker, B. Derivate von 
steroidbenzylaminen mit antiparasitärer, antibakterieller, 
antimykotischer und/oder antiviraler wirkung. 2012, DE 
102010047714 A1.
52. Bora, P. P.; Baruah, N.; Bez, G.; Barua, N. C. New Method for 
the Synthesis of Ether Derivatives of Artemisinin. Synth. Commun. 
2012, 42, 1218-1225.
53. Fröhlich, T.; Reiter, C.; Ibrahim, M. M.; Beutel, J.; Hutterer, C.; 
Zeitträger, I.; Bahsi, H.; Leidenberger, M.; Friedrich, O.; Kappes, B.; 
Efferth, T.; Marschall, M.; Tsogoeva, S. B. Synthesis of Novel Hybrids 
of Quinazoline and Artemisinin with High Activities against 
Plasmodium falciparum, Human Cytomegalovirus, and Leukemia 
Cells. ACS Omega 2017, 2, 2422-2431.
54. Fröhlich, T.; Çapc ı  Karagöz, A.; Reiter, C.; Tsogoeva, S. B. 
Artemisinin-Derived Dimers: Potent Antimalarial and Anticancer 
Agents. J. Med. Chem. 2016, 59, 7360-7388.
55. Marschall, M.; Freitag, M.; Weiler, S.; Sorg, G.; Stamminger, T. 
Recombinant Green Fluorescent Protein-Expressing Human 
Cytomegalovirus as a Tool for Screening Antiviral Agents. Antimicrob. 
Agents Chemother. 2000, 44, 1588-1597.
56. Marschall, M.; Niemann, I.; Kosulin, K.; Bootz, A.; Wagner, S.; 
Dobner, T.; Herz, T.; Kramer, B.; Leban, J.; Vitt, D.; Stamminger, T.; 
Hutterer, C.; Strobl, S. Assessment of drug candidates for broad-
spectrum antiviral therapy targeting cellular pyrimidine biosynthesis. 
Antiviral Res. 2013, 100, 640-648.
57. Hutterer, C.; Eickhoff, J.; Milbradt, J.; Korn, K.; Zeitträger, I.; 
Bahsi, H.; Wagner, S.; Zischinsky, G.; Wolf, A.; Degenhart, C.; Unger, 
A.; Baumann, M.; Klebl, B.; Marschall, M. A novel CDK7 inhibitor of 
the Pyrazolotriazine class exerts broad-spectrum antiviral activity at 
nanomolar concentrations. Antimicrob. Agents Chemother. 2015, 59, 
2062-2071.
58. Hutterer, C.; Niemann, I.; Milbradt, J.; Fröhlich, T.; Reiter, C.; 
Kadioglu, O.; Bahsi, H.; Zeitträger, I.; Wagner, S.; Einsiedel, J.; 
Gmeiner, P.; Vogel, N.; Wandinger, S.; Godl, K.; Stamminger, T.; 
Efferth, T.; Tsogoeva, S. B.; Marschall, M. The broad-spectrum 
antiinfective drug artesunate interferes with the canonical nuclear 
factor kappa B (NF-kappaB) pathway by targeting RelA/p65. Antiviral 
Res. 2015, 124, 101-109.
Page 6 of 7
ACS Paragon Plus Environment
ACS Medicinal Chemistry Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
7For Table of Contents Use Only
O
O
H
X
O
O
Y
H
H H
O
R
H
Linker
0.45 µM
0.18 µM
0.15 µM
3.80 nM
0.22 µM
EC50 (MCF7)
EC50 (MDA-MB-361)
EC50 (C33A)
EC50 (P. f. 3D7)
EC50 (HCMV)
Artemisinin-Estrogen Hybrids
anticancer
antimalarial
antiviral
Page 7 of 7
ACS Paragon Plus Environment
ACS Medicinal Chemistry Letters
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
